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Abstract: A series of sulfamates were synthesized using as lead compoundSLC-0111, a sulfonamide carbonic 
anhydrase (CA, EC 4.2.1.1) inhibitor in Phase I clinical trials. The new derivatives incorporated ureido moieties 
as spacers between the benzene sulfamate fragment which binds the zinc ion from the active site, and the tail of 
the inhibitor, but the urea moieties were part of a substituted piperazine ring system. The derivatives (and some 
of their phenol precursors) were tested for the inhibition of the cytosolic, hCA I and II (offtargetisoforms) and 
the trans-membrane, tumor-associated hCA IX and XII enzymes (anticancer drug targets). Generally hCA I was 
not effectively inhibited, whereas many low nanomolar inhibitors were evidenced against hCA II (KIs in the 
range of 1.0 – 94.4 nM) IX (KIs in the range of 0.91 – 36.9 nM), and XII (KIs in the range of 1.0 – 84.5 nM). 
The best substitution fragments at the piperazine ring included the following moieties: 3-methylphenyl, 2,3-
dimethylphenyl, 4-methoxyphenyl, 6-arylpyrimidine-2-yl. 
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1. Introduction 
 
 The carbonic anhydrases (CAs, EC 4.2.1.1) represent a superfamily of widespread enzymes which 
catalyze a crucial biochemical reaction, the reversible hydration of CO2 to bicarbonate and protons.1-4 These 
three simple ions/molecules acting as substrates/reaction products in this process are involved in a range of 
physiologic processes related to pH regulation, electrolyte secretion, chemosensing, biosynthetic reactions 
involving carboxylating enzymes (gluconeogenesis, lipogenesis, ureagenesis, etc.), and as thus, their formation 
is tightly controlled in organisms all over the phylogenetic tree.1-4 This is probably the reason why at least six 
unrelated genetic families encode for CAs (the α, β, γ, δ, ζ and therecently proposed group ofη-CAs).5-8 
Furthermore, in most organisms investigated in detail, a large number of isoforms of the CA family are present, 
which possess specialized functions in various tissues/organs, also having a diversified catalytic activity, and 
susceptibility to be inhibited or activated by various modulators of activity.1-4 For example, in humans 15 α-CA 
isoforms were described, hCA I-hCA VA, hCA VB-hCA XIV, whereas the non-primate mammals have an 
additional isoform hCA XV. In mammals the isoform hCA XVII has been lost, but it is however present in 
other vertebrates.9Such a multitude of CA isoforms present in these organisms and their diverse subcellular 
localization (as there are cytosolic, mitochondrial, trans-membrane and secreted CA isoforms)1-4,9prove that the 
high amounts of CO2 generated in metabolic processes must be efficiently converted to bicarbonate (plus 
protons), and indeed, some α-CAs are among the most effective catalysts known in nature.10 
 There are some forms of cancer in which some CA isoforms were observed to be overexpressed, such as 
CA IX and XII and more rarely CA II.11CA II is also involved in other pathologies such as acute mountain 
sickness (AMS) and apparently, atherosclerosis and osteoporosis.12 Many of the hCAs are drug targets for 
diuretics, anticonvulsants, antiglaucoma agents, and antitumor/antimetastatic drugs.1-4,13 Recently a 
sulfonamide CA inhibitor (CAI) developed by our group, SLC-011114 entered Phase I clinical trials for the 
treatment of patients with advanced solid, metastatic tumors overexpressing CA IX/XII.14 Unlike the 
prototypical sulfonamide CAI acetazolamide (AAZ), SLC-0111 is a selective inhibitor for the trans-membrane, 
tumor-associated isoforms hCA IX/XII over the cytosolic widespread isoforms hCA I and II.14 
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 One of the main features of SLC-0111 and the series of compounds to which it belongs,14a is the 
presence of the ureido functionality as linker between the benzenesulfonamide fragment (which binds to the 
metal ion from the CA active site) and the tail of the inhibitor. By means of X-ray crystallography (for SLC-
0111 and a series of other four of its congeners complexed to hCA II), we demonstrated that the reasons for the 
isoform selectivity is the ureido linker, which allows a great flexibility to the tails present in these moleculesand 
  
the possibility for the inhibitor to adopt a variety of orientations when complexed within the enzyme active 
site.14a,d These tails bind towards the entrance of the CA active site cavity, which is the most diverse region 
among the many isoforms with medicinal chemistry applications, such as for example CA I, II, IX and XII. As 
few CAIs incorporating ureido linkers were reported so far, in this paper we report a novel such series. A series 
of sulfamates incorporating the ureido linker mentioned above and substituted piperazinyl moieties were 
prepared and assayed for the inhibition of the two widespread cytosolic isoforms hCA I and II, as well as the 
transmembrane, tumor-associated ones hCA IX and XII. 
 
2. Results and Discussion 
2.1. Chemistry. 
 
The rationale for the drug design of the compounds reported here is a rather simple one. We used SLC-0111 as 
lead molecule, as this compound is a low nanomolar, CA IX/XII-selective inhibitor (over CA I and II), with a 
significant antitumor activity in animal models of hypoxic tumors, andit also shows a good bioavailability.13,14 
We report here a series of compounds possessing two major modifications compared to the lead SLC-0111: (i) 
the sulfonamide zinc-binding group (ZBG) from the lead was replaced by the isosteric sulfamate15 one in the 
compounds, and (ii) the left part of the ureido moiety from the lead SLC-0111was incorporated into a more 
rigid heterocyclic system, i.e., the substituted piperazine one. We incorporated into the scaffolds of the new 
sulfamates4 a large number of aromatic/heterocyclic moieties (substituting the second nitrogen atom from the 
piperazine ring) in order to generate chemical diversity and also because the terminal part of the inhibitor, far 
from the ZBG, usually interactswith the entrance of the CA active site cavity.1-4 As that is the region with most 
diverse amino acid residues among the different α-CAs, selective inhibition may be achieved through particular 
interactions between the tail of the inhibitor and this region of the active site, as demonstrated by a large 
number of X-ray crystallographic studies of enzyme-inhibitor complexes.1,3,4 
The synthesis of the new compounds is reported in Schemes 1 and 2. Sulfamoylation of phenyl 
carbamate 116upon treatment with sulfamoyl chloride17in N,N-dimethylacetamide (DMA) solution furnished the 
key intermediate 2 in 82% yield. Coupling of 2with 1-substituted piperazines3a-k in DMSO solution gavethe 
piperazinyl urea derivatives 4a-k in 42-93% yields. In a similar manner, the phenyl carbamate 1 reacted with 
piperazines3a-e to produce the phenolic derivatives 5a-e in 56-88% yields (Scheme 1). The pyrimidinyl-
piperazines3i-kwere synthesized by heterocyclization of 4-Boc-piperazine-1-carboxamidine 618 with 3-
(dimethylamino)propenones7-9in boiling n-propanol, followed by trifluoroacetic acid (TFA)-
mediateddeprotectionin dichloromethane (DCM) solution (Scheme 2). Indeed, phenols were also reported to act 
as CAIs, although their mechanism of action is different compared to the sulfonamides, as they anchor to the 
zinc-coordinated water molecule.19 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 1.Reagents and conditions: i) Sulfamoyl chloride, DMA, 0 °C to r.t., overnight; ii) DMSO, r.t., 18h. 
 
 
 
 
Scheme 2.Reagents and conditions: i) 1-PrOH, reflux, 6h; ii) TFA, DCM, r.t., overnight. 
 
 
 
2.2. CA inhibition 
 
Sulfamates4a-4kand phenols 5a-5ewere screened20 for the inhibition of four human (h) CA isoforms involved 
in important physiologic/pathologic processes, i.e., the cytosolic, hCA I and II (off-targets in this case) and the 
trans-membrane, tumor-associated hCA IX and XII (anticancer drug targets).11-13Table 1 shows inhibition data 
of the derivatives reported here and the sulfonamide acetazolamide AAZ(as standard inhibitor) against hCA I, 
II, IX and XII, after a period of 15 min of incubation of the enzyme and inhibitor solutions.20-23The 
followingstructure activity relationship (SAR)may be noted regarding the inhibition data of Table 1: 
(i) The slow cytosolic isoform hCA I was effectively inhibited by one sulfamate (4c, KI of 9.4 nM), rather well 
inhibited by other three sulfamates from the new series (4f, 4g and 4k, with inhibition constants ranging 
between 63.5 and 88.1 nM, Table 1) whereas the remaining sulfamates were much weaker inhibitors (KIs in the  
 
 
3-5a: 
b: 
c: 
d: 
R = benzyl 
R = phenyl 
R = 4-F-phenyl 
R = 4-Cl-phenyl  
e: 
f: 
g: 
h: 
R = 3-Me-phenyl 
R = 2,3-Me2-phenyl 
R = 3-MeO-phenyl 
R = 4-MeO-phenyl 
i: 
j: 
k: 
R = 4-(4-Br-phenyl)pyrimidin-2-yl 
R = 4-(4-CF3-phenyl)pyrimidin-2-yl 
R = 4-benzofuran-2-ylpyrimidin-2-yl 
  
Table 1: Inhibition data of human (h) CA isoforms hCA I, II, IX and XII with sulfamates4a-k and phenols 5a-
e, and the standard sulfonamide inhibitor acetazolamide (AAZ) by a stopped flow CO2hydrase assay.20 
 
   KI (nM)* 
 Compound R hCA I hCA II hCA IX hCA XII 
 4a 
 
316.5 11.7 10.5 1.0 
 4b 
 
896.8 71.9 11.1 1.0 
 4c 
 
9.4 18.2 61.5 64.7 
 4d 
 
581.3 16.9 10.4 84.5 
 4e 
 
851.5 15.9 0.91 35.8 
 4f 
 
63.5 11.1 32.3 1.0 
 4g 
 
88.1 11.2 34.1 37.0 
 4h 
 
282.4 9.1 114.1 1.1 
 4i 
 
277.2 1.2 113.6 1.0 
 4j 
 
290.9 1.1 24.3 1.0 
 4k 
 
70.2 1.0 6.7 1.0 
 5a 
 
>10000 94.4 112.9 7.9 
 5b 
 
300.4 81.6 120.7 7.1 
 5c 
 
799.8 5935.6 36.9 6.3 
 5d 
 
>10000 519.5 80.5 8.6 
 5e 
 
5296.1 1427.7 549.2 9.5 
 AAZ - 250 12 25 5.7 
 
* Mean from 3 different assays (errors were in the range of ± 5-10 % of the reported values). 
 
 
 
range of 277.2 – 896 nM. It may be observed that the effective hCA I inhibitors incorporate 4-fluorophenyl-, 
2,3-dimethylphenyl- and 3-methoxyphenyl moieties at the 4-nitrogen atom of the piperazine ring, whereas 
  
small differences in the nature of the R moiety or the substitution pattern (e.g., F from 4c replaced by H or Cl, 
as in 4b and 4d) lead to dramatic changes in the inhibition constant of the inhibitor, proving probably that our 
working hypothesis (i.e., interaction of the tail from the inhibitor molecule with the amino acid residues at the 
entrance of the active site) is correct. The phenols 5 were also poorly active (5b and 5c with KIs in the range of 
300.4 – 799.8 nM) or inactive (KIs > 5 µM, for 5a, 5d and 5e, Table 1). Acetazolamide (AAZ) is a medium 
potency hCA I inhibitor with a KI of 250 nM. 
(ii) hCA II, the dominant physiologic isoform,1 was potently inhibited by all sulfamates4, with KIs in the range 
of 1.0 – 71.9 nM, in the same activity range as AAZ (KI of 12 nM). Thus, the SAR is quite flat in this case, 
although three compounds (4i, 4j and 4k) have inhibition constants of 1.0 – 1.2 nM being thus an order of 
magnitude more effective inhibitors compared to the remaining ones. All of them incorporate the long tail 
based on the 6-substituted-pyrimidine scaffold. It is thus obvious that the compounds with this elongated 
scaffold make excellent contacts with the rim of the active site entrance of hCA II, leading thus to low 
nanomolar inhibition. The remaining sulfamates (4a-4g) incorporating benzyl or substituted phenyl moieties at 
the piperazine ring also showed a rather compact inhibitory power with KIs in the range of 11.1 – 18.2 nM, 
except for 4b, which was the weakest inhibitor in the series, with a KI of 71.9 nM. In fact this derivative does 
not have substituents on the phenyl ring, which as it may be observed, is detrimental for the hCA II inhibition. 
Two of the reported phenols (5a and 5b) had KIs < 100 nM whereas the remaining ones were ineffective as 
hCA II inhibitors (Table 1). 
(iii) hCA IX, the tumor-associated isoform, was also effectively inhibited by many of the sulfamates reported 
here. Indeed, compounds 4a, 4b, 4d-4g, 4j, 4k and 5c showed KIs in the range of 0.91 – 36.9 nM, being thus 
more effective or in the same range of activity as AAZ, a compound for which a notable anticancer activity was 
reported in some animal models of hypoxic tumors.24 It may be noted that for the sulfamates the substitution 
patterns at the piperazine ring leading to the best hCA IX inhibition included the 3-methylphenyl moiety (in 
4e), the benzofuran-pyrimidinyl (in sulfamate4k) as well as the 4-fluorophenyl in the phenol 5c. For the pair 
4c/5c, it is noteworthy that the phenol shows a better hCA IX inhibition profile compared to the sulfamate, 
whereas for all other sulfamate/phenol pairs, the sulfamate was a much more potent enzyme inhibitor compared 
to the corresponding phenol (Table 1). The remaining sulfamates/phenols (4c, 4h, 4i, 5a, 5b, 5d) showed 
moderate hCA IX inhibitory activity with KIs in the range of 61.5 – 120.7 nM. The weakest inhibitor in the 
series of investigated compounds was the phenol 5e, with a KI of 549.2 nM (Table 1). 
(iv) A very interesting inhibition profile with the sulfamates/phenols investigated here was observed for the 
second transmembrane isoform, hCA XII. Indeed, many sulfamates (4a, 4b, 4f, 4h-4k) had a very potent 
inhibitory effect with KIs varying very little (the range of 1.0 – 1.1 nM) whereas the remaining ones (4c-4e and 
4g) were slightly less potent (KIs in the range of 35.8 – 84.5 nM) Thus, most of the substitution patterns present 
in these sulfamates are beneficial for obtaining very effective hCA XII inhibitors (e.g., benzyl, phenyl, 2,3-
dimethylphenyl, 4-methoxyphenyl, substituted-pyrimidinyl). The phenols on the other hand were also highly 
effective hCA XII inhibitors, with KIs in the range of 6.3 – 9.5 nM (the same as AAZ). Basically hCA XII was 
the most sensitive isoform to be inhibited by the compounds reported here. 
  
(v) The compounds reported here do not show a marked isoform-selectivity effect (as compared to the SLC-
0111 series used as lead).14a However many of the new sulfamates/phenols showed excellent hCA II and XII 
inhibitory effects (in the low nanomolar range) and good selectivity for these two isoforms over hCA I and IX, 
which is a very interesting profile not observed earlier with any other class of CAIs. As hCA II and XII are the 
two isoforms mainly involved in glaucoma,4,12 it would be of interest to test some of these derivatives in vivo 
for antiglaucoma effects. 
 
3. Conclusions 
 
A series of sulfamates were synthesized using SLC-0111, a sulfonamide CAI in Phase I clinical trials, as lead 
compound. The new derivatives incorporated ureido moieties as spacers between the benzene sulfamate 
fragment which binds the zinc ion from the active site, and the tail of the inhibitor, but the urea moieties were 
part of a substituted piperazine ring system. The derivatives (and some of their phenol precursors) were tested 
for the inhibition of the cytosolic, hCA I and II (off-target isoforms) and the transmembrane, tumor-associated 
hCA IX and XII enzymes (anticancer drug targets). Generally hCA I was not effectively inhibited, whereas 
many low nanomolar inhibitors were evidenced against hCA II (KIs in the range of 1.0 – 94.4 nM) IX (KIs in 
the range of 0.91 – 36.9 nM), and XII (KIs in the range of 1.0 – 84.5 nM). The best substitution fragments at the 
piperazine ring included the following moieties: 3-methylphenyl, 2,3-dimethylphenyl, 4-methoxyphenyl, 6-
arylpyrimidine-2-yl. 
 
4. ExperimentalSection 
4.1. Chemistry. 
Unless otherwise noted, all solvents, including anhydrous solvents and chemicals, were purchased from Aldrich 
Co. and/or Alfa Aesar, and used without further purification. Melting points were recorded on a Stuart 
Scientific melting point SMP1 apparatus and are uncorrected. Positive-ion electrospray ionization (ESI) mass 
spectra were recorded on a double-focusing Finnigan MAT 95 instrument with BE geometry. Proton nuclear 
magnetic resonance spectra were recorded on a Varian Inova 500 spectrometer at 500 MHz, in DMSO-d6 as the 
solvent,and TMS as the internal standard. Chemical shifts are expressed in ppm relative to tetramethylsilane. 
Splitting patterns are designated as singlet (s), doublet (d), triplet (t), quartet (q), and multiplet (m). Infrared 
spectra were run on Bruker Vector 22 spectrophotometer. Reaction courses and product mixtures were 
routinely monitored by TLC on silica gel (precoated F254 Merck plates). Developed plates were visualized by a 
Spectroline ENF 260C/F UV apparatus. Concentration and evaporation of the solvent after reaction or 
extraction were carried out on a rotary evaporator (BüchiRotavapor) operating at reduced pressure. Elemental 
analyses were carried out with a Carlo Erba model 1106 elemental analyzer, and all values were within 0.4% of 
the calculated values, which indicates >95% purity of the tested compounds. 
 
  
4-(Phenoxycarbonyl)aminophenylsulfamate (2). To a stirred ice-cooled solution of phenyl (4-
hydroxylphenyl)carbamate (1) (4.6 g, 20 mmol) in anhydrous DMA (50 mL), freshly prepared sulfamoyl 
chloride ( 60 mmol) in DMA (10 mL) was added dropwise in 30 min. The reaction mixture was stirred at room 
temperature overnight, then water (100 mL) was added; the mixture was stirred for additional 2 h, the formed 
solid filtered off, and vacuum dried to give sulfamate2 in good purity to be used in the next step without further 
purification.5.01 g, 82% yield,mp 165-168 °C. ESI-MS (m/z): 309 (M + H)+. 1HNMR: δ 7.23 (m, 4H), 7.43 (m, 
3H), 7.55 (m, 2H), 7.91 (s, 2H), 10.32 (s, 1H); IR (Nujol) 3383, 3336, 3242, 1726 cm-1. 
 
Preparation of 1-(4-arylpyrimidin-2-yl)piperazines 3i-k. Typical procedure: 1-(4-(4-bromophenyl)-
pyrimidin-2yl)piperazine (3i). A solution of 1-(4-bromophenyl)-3-(dimethylamino)prop-2-en-1-one25(7, 0.51 
g, 2 mmol) and 4-(tert-butoxycarbonyl)piperazine-1-carboxamidine (6, 0.46 g, 2 mmol) in anhydrous 1-PrOH 
(5 mL) was refluxed 6 h. The solvent was removed under reduced pressure, the residue was suspended in 
dichloromethane (10 mL) and treated with trifluoroacetic acid (5 mL). The mixture was stirred at room 
temperature overnight; after evaporation of the solvent, the residue was treated with iso-propyl ether, the 
formed solid was filtered off, and dried in vacuum, to give 3i as trifluoroacetate salt in good purity to be used in 
the next step without further purification. 0.64 g, 74% yield,mp 218-221 °C. ESI-MS (m/z): 320 (M + H)+. 
1HNMR: δ 3.17 (m, 4H), 4.07 (m, 4H), 7.34 (d, J = 4.7 Hz, 1H), 7.72 (d, J = 6.0 Hz, 2H), 8.12 (d, J = 6.0 Hz, 
2H), 8.52 (d, J = 4.7 Hz, 1H), 9.52 (br, 2H); IR (Nujol) 2860, 1669, 1580 cm-1. 
 
1-(4-(4-Trifluoromethylphenyl)-pyrimidin-2-yl)piperazine (3j). Obtained from 1-(4-trifluoromethylphenyl)-
3-(dimethylamino)-prop-2-en-1-one 26(8) following the typical procedure as 3i. 0.56 g, 67%, mp 176-178 °C. 
ESI-MS (m/z): 309 (M + H)+. 1HNMR: δ 3.24 (m, 4H), 4.07 (m, 4H), 7.75 (d, J = 4.6 Hz, 1H), 7.89 (d, J = 5.8 
Hz, 2H), 8.37 (d, J = 5.8 Hz, 2H), 8.60 (d, J = 4.6 Hz, 1H), 9.08 (br, 2H); IR (Nujol) 2840, 1662, 1584 cm-1. 
 
1-(4-(Benzofuran-2-yl)pyrimidin-2-yl)piperazine (3k). Obtained from 1-benzofuran-2-yl-3-(dimethylamino)-
prop-2-en-1-one 27(9) following the typical procedure as 3i. 0.66 g, 84%, mp 176-178 °C. ESI-MS (m/z): 281 
(M + H)+. 1HNMR: δ 3.21 (m, 4H), 4.07 (m, 4H), 7.24 (d, J = 4.9 Hz, 1H), 7.34 (m, 1H), 7.45 (m, 1H), 7.70 
(m, 1H), 7.78 (m, 1H), 7.82 (s, 1H), 8.58 (d, J = 4.9 Hz, 1H), 9.33 (br, 2H); IR (Nujol) 2886, 1678, 1575 cm-1. 
 
General procedure for the preparation of 4-(piperazinocarbonyl)aminophenylsulfamates 4a-k, and 4-
(piperazinocarbonyl)aminophenols5a-e. A mixture of 1-substituted piperazine3a-k (1 mmol) and 4-
(phenoxycarbonyl)aminophenylsulfamate (2, 0.31 g, 1 mmol) or phenyl (4-hydroxylphenyl)carbamate (1, 0.23 
g, 1 mmol) in anhydrous DMSO (5 mL) was stirred at room temperature for 18 h. The reaction mixture was 
then diluted with water (10 mL); the formed solid was collected and washed with water, air dried, and 
crystallized fromEtOH to give 4a-k, and 5a-e. 
 
  
4-(4-Benzylpiperazinocarbonyl)aminophenylsulfamate(4a). Following the general procedure, the title 
compound was obtained from 3a. 0.28 g, 73%, mp 168-170 °C. ESI-MS (m/z): 391 (M + H)+. 1HNMR: δ 2.37 
(m, 4H), 3.43 (m, 4H), 3.50 (s, 2H), 7.13 (d, J = 7.5 Hz, 2H), 7.25 (m, 2H), 7.31 (m, 3H), 7.47 (d, J = 7.5 Hz, 
2H), 7.73 (br s, 2H), 8.58 (s, 1H); IR (Nujol) 3419, 3323, 1649 cm-1. Anal.Calcd for C18H22N4O4S: C, 55.37; H, 
5.68; N, 14.35. Found: C, 55.30; H, 5.63; N, 14.31. 
 
4-(4-Phenylpiperazinocarbonyl)aminophenylsulfamate(4b). Following the general procedure, the title 
compound was obtained from 3b. 0.31 g, 83%, mp 196-198 °C. ESI-MS (m/z): 377 (M + H)+. 1HNMR: δ 3.15 
(m, 4H), 3.59 (m, 4H), 6.80 (m, 2H), 6.98 (d, J = 7.0 Hz, 2H), 7.15 (m, 2H), 7.23 (m, 3H), 7.84 (br s, 2H), 8.71 
(s, 1H); IR (Nujol) 3411, 3306, 1642 cm-1. Anal.Calcd for C17H20N4O4S: C, 54.24; H, 5.36; N, 14.88. Found: C, 
54.19; H, 5.30; N, 14.81. 
 
4-(4-(4-Fluorophenyl)piperazinocarbonyl)aminophenylsulfamate (4c). Following the general procedure, the 
title compound was obtained from 3c. 0.25 g, 64%, mp 188-190 °C. ESI-MS (m/z): 395 (M + H)+. 1HNMR: 
δ 3.10 (m, 4H), 3.59 (m, 4H), 7.00 (m, 2H), 7.06 (m, 2H), 7.14 (d, J = 8.8 Hz, 2H), 7.51 (d, J = 8.8 Hz, 2H), 
7.86 (s, 2H), 8.70 (s, 1H); IR (Nujol) 3368, 3188, 1661 cm-1. Anal.Calcd for C17H19FN4O4S: C, 51.77; H, 4.86; 
N, 14.20. Found: C, 51.72; H, 4.85; N, 14.14. 
 
4-(4-(4-Chlorophenyl)piperazinocarbonyl)aminophenylsulfamate (4d). Following the general procedure, 
the title compound was obtained from 3d. 0.38 g, 93%, mp 192-194 °C. ESI-MS (m/z): 412 (M + H)+. 1HNMR: 
δ 3.16 (m, 4H), 3.58 (m, 4H), 6.98 (m, 2H), 7.14 (d, J = 7.3 Hz, 2H), 7.23 (m, 2H), 7.50 (d, J = 7.3 Hz, 2H), 
7.86 (s, 2H), 8.70 (s, 1H); IR (Nujol) 3418, 3256, 1640 cm-1. Anal.Calcd for C17H19ClN4O4S: C, 49.69; H, 4.66; 
N, 13.64. Found: C, 49.61; H, 4.60; N, 13.58. 
 
4-(4-(3-Methylphenyl)piperazinocarbonyl)aminophenylsulfamate (4e). Following the general procedure, 
the title compound was obtained from 3e. 0.30 g, 78%, mp 202-204 °C. ESI-MS (m/z): 391 (M + H)+. 1HNMR: 
δ 2.26 (s, 3H), 3.14 (m, 4H), 3.58 (m, 4H), 6.63 (m, 1H), 6.98 (m, 2H), 7.14 (m, 3H), 7.51 (d, J = 6.3 Hz, 2H), 
7.72 (br s, 2H), 8.71 (s, 1H); IR (Nujol) 3373, 3208, 1658 cm-1. Anal.Calcd for C18H22N4O4S: C, 55.37; H, 
5.68; N, 14.35. Found: C, 55.32; H, 5.64; N, 14.27. 
 
4-(4-(2,3-Dimethylphenyl)piperazinocarbonyl)aminophenylsulfamate (4f). Following the general 
procedure, the title compound was obtained from 3f. 0.17 g, 42%, mp 176-178 °C. ESI-MS (m/z): 405 (M + 
H)+. 1HNMR: δ 2.19 (s, 3H), 2.21 (s, 3H), 2.80 (m, 4H), 3.60 (m, 4H), 6.89 (m, 2H), 7.04 (m, 1H), 7.14 (d, J = 
8.8 Hz, 2H), 7.51 (d, J = 8.8 Hz, 2H), 7.86 (s, 2H), 8.68 (s, 1H); IR (Nujol) 3353, 3196, 3097, 1648 cm-1. 
Anal.Calcd for C19H24N4O4S: C, 56.42; H, 5.98; N, 13.85. Found: C, 56.37; H, 5.94; N, 13.77. 
 
  
4-(4-(3-Methoxyphenyl)piperazinocarbonyl)aminophenylsulfamate (4g). Following the general procedure, 
the title compound was obtained from 3g. 0.24 g, 59%, mp 193-195 °C. ESI-MS (m/z): 407 (M + H)+. 1HNMR: 
δ 3.15 (m, 4H), 3.57 (m, 4H), 3.71 (s, 3H), 6.39 (m, 1H), 6.49 (s, 1H); 6.56 (m, 1H), 7.14 (m, 3H), 7.51 (d, J = 
8.8 Hz, 2H), 7.80 (br s, 2H), 8.70 (s, 1H); IR (Nujol) 3383, 3179, 1657 cm-1. Anal.Calcd for C18H22N4O5S: C, 
53.19; H, 5.46; N, 13.78. Found: C, 53.14; H, 5.40; N, 13.72. 
 
4-(4-(4-Methoxyphenyl)piperazinocarbonyl)aminophenylsulfamate (4h). Following the general procedure, 
the title compound was obtained from 3h. 0.32 g, 80%, mp 190-192 °C.ESI-MS (m/z): 407 (M + H)+. 1HNMR: 
δ 3.02 (m, 4H), 3.58 (m, 4H), 3.68 (s, 3H), 6.83 (d, J = 8.8 Hz, 2H), 6.93 (s, 2H); 7.14 (d, J = 8.8 Hz, 2H), 7.50 
(d, J = 8.8 Hz, 2H), 7.86 (s, 2H), 8.69 (s, 1H); IR (Nujol) 3406, 3284, 1638 cm-1. Anal.Calcd for C18H22N4O5S: 
C, 53.19; H, 5.46; N, 13.78. Found: C, 53.12; H, 5.41; N, 13.70. 
 
4-(4-(4-(4-Bromophenyl)pyrimidin-2-yl)piperazinocarbonyl)aminophenyl sulfamate (4i). Following the 
general procedure, the title compound was obtained from 3i in presence of equimolar amounts of DIPEA. 0.41 
g, 76%, mp 176-178 °C. ESI-MS (m/z): 534 (M + H)+. 1HNMR: δ 3.58 (m, 4H), 3.89 (m, 4H), 7.15 (d, J = 8.8 
Hz, 2H), 7.26 (d, J = 4.9 Hz, 1H), 7.52 (d, J = 8.8 Hz, 2H), 7.71 (d, J = 8.3 Hz, 2H), 7.86 (br s, 2H), 8.10 (d, J = 
8.3 Hz, 2H), 8.48 (d, J = 4.9 Hz, 1H), 8.72 (s, 1H); IR (Nujol) 3357, 3264, 1644 cm-1. Anal.Calcd for 
C21H21BrN6O4S: C, 47.29; H, 3.97; N, 15.76. Found: C, 47.23; H, 3.94; N, 15.69. 
 
4-(4-(4-(4-Trifluoromethylphenyl)pyrimidin-2-yl)piperazinocarbonyl)aminophenyl sulfamate (4j). 
Following the general procedure, the title compound was obtained from 3j in presence of equimolar amounts of 
DIPEA. 0.34 g, 66%, mp 152-154 °C. ESI-MS (m/z): 523 (M + H)+. 1HNMR: δ 3.59 (m, 4H), 3.89 (m, 4H), 
7.15 (d, J = 8.8 Hz, 2H), 7.32 (m, 1H), 7.52 (d, J = 8.8 Hz, 2H), 7.80 (br s, 2H), 7.88 (d, J = 7.3 Hz, 2H), 8.34 
(d, J = 7.3 Hz, 2H), 8.54 (m, 1H), 8.73 (s, 1H);  IR (Nujol) 3407, 3319, 1645 cm-1. Anal.Calcd for 
C22H21F3N6O4S: C, 50.57; H, 4.05; N, 16.08. Found: C, 50.50; H, 4.04; N, 16.00. 
 
4-(4-(4-Benzofuran-2-ylpyrimidin-2-yl)piperazinocarbonyl)aminophenyl sulfamate (4k). Following the 
general procedure, the title compound was obtained from 3k in presence of equimolar amounts of DIPEA. 0.36 
g, 73%, mp 146-148 °C. ESI-MS (m/z): 495 (M + H)+. 1HNMR: δ 3.59 (m, 4H), 3.89 (m, 4H), 7.17 (m, 3H), 
7.33 (m, 1H), 7.44 (m, 1H), 7.52 (d, J = 8.8 Hz, 2H), 7.70 (m, 1H), 7.78 (m, 2H), 7.87 (s, 2H), 8.54 (d, J = 4.9 
Hz, 1H), 8.74 (s, 1H); IR (Nujol) 3410, 3321, 3103, 1648 cm-1. Anal.Calcd for C23H22N6O5S: C, 55.86; H, 4.48; 
N, 16.99. Found: C, 55.79; H, 4.45; N, 16.92. 
 
4-(4-Benzylpiperazinocarbonyl)aminophenol(5a). Following the general procedure, the title compound was 
obtained from 3a. 0.23 g, 74%, mp 182-184 °C.ESI-MS (m/z): 312 (M + H)+. 1HNMR: δ 2.35 (m, 4H), 3.39 (m, 
4H), 3.49 (s, 2H), 6.60 (d, J = 8.0 Hz, 2H), 7.15 (d, J = 8.0 Hz, 2H), 7.25 (m, 1H), 7.31 (m, 4H), 8.17 (s, 1H), 
  
8.95 (s, 1H); IR (Nujol) 3414, 3263, 1634 cm-1. Anal.Calcd for C18H21N3O2: C, 69.43; H, 6.80; N, 13.49. 
Found: C, 69.36; H, 6.73; N, 13.42. 
 
4-(4-Phenylpiperazinocarbonyl)aminophenol(5b). Following the general procedure, the title compound was 
obtained from 3b. 0.24 g, 82%, mp 228-230 °C.ESI-MS (m/z): 298 (M + H)+. 1HNMR: δ 3.13 (m, 4H), 3.55 
(m, 4H), 6.63 (d, J = 8.5 Hz, 2H), 6.80 (m, 1H), 6.97 (d, J = 8.5 Hz, 2H), 7.20 (m, 4H), 8.31 (s, 1H), 8.97 (s, 
1H); IR (Nujol) 3436, 3178, 1649 cm-1. Anal.Calcd for C17H19N3O2: C, 68.67; H, 6.44; N, 14.13. Found: C, 
68.62; H, 6.42; N, 14.08. 
 
4-(4-(4-Fluorophenyl)piperazinocarbonyl)aminophenol (5c). Following the general procedure, the title 
compound was obtained from 3c. 0.28 g, 88%, mp 208-210 °C.ESI-MS (m/z): 316 (M + H)+. 1HNMR: δ 3.07 
(m, 4H), 3.54 (m, 4H), 6.63 (d, J = 8.5 Hz, 2H), 6.98 (m, 2H), 7.05 (m, 2H), 7.19 (d, J = 8.5 Hz, 2H), 8.30 (s, 
1H), 8.97 (s, 1H); IR (Nujol) 3455, 3201, 1652 cm-1. Anal.Calcd for C17H18FN3O2: C, 64.75; H, 5.75; N, 13.33. 
Found: C, 64.68; H, 5.70; N, 13.27. 
 
4-(4-(4-Chlorophenyl)piperazinocarbonyl)aminophenol (5d). Following the general procedure, the title 
compound was obtained from 3d. 0.18 g, 56%, mp 225-227 °C.ESI-MS (m/z): 333 (M + H)+. 1HNMR: δ 3.14 
(m, 4H), 3.54 (m, 4H), 6.61 (d, J = 8.0 Hz, 2H), 6.98 (d, J = 8.5 Hz, 2H), 7.19 (d, J = 8.0 Hz, 2H), 7.23 (d, J = 
8.5 Hz, 2H), 8.31 (s, 1H), 8.97 (s, 1H);IR (Nujol) 3432, 3242, 1654 cm-1. Anal.Calcd for C17H18ClN3O2: C, 
61.54; H, 5.47; N, 12.66. Found: C, 61.49; H, 5.42; N, 12.58. 
 
4-(4-(3-Methylphenyl)piperazinocarbonyl)aminophenol (5e). Following the general procedure, the title 
compound was obtained from 3e. 0.24 g, 79%, mp 208-210 °C.ESI-MS (m/z): 312 (M + H)+. 1HNMR: δ 2.25 
(s, 3H), 3.11 (m, 4H), 3.54 (m, 4H), 6.63 (m, 3H), 6.79 (m, 2H), 7.10 (m, 1H), 7.19 (d, J = 8.5 Hz, 2H), 8.30 (s, 
1H), 8.97 (s, 1H); IR (Nujol) 3316, 3298, 1636 cm-1. Anal.Calcd for C18H21N3O2: C, 69.43; H, 6.80; N, 13.49. 
Found: C, 69.36; H, 6.78; N, 13.42. 
 
4.2. CA inhibition 
 
An Applied Photophysics stopped-flow instrument has been used for assaying the CA catalyzed CO2 hydration 
activity.20 Phenol red (at a concentration of 0.2 mM) has been used as indicator, working at the absorbance 
maximum of 557 nm, with 20 mMHepes (pH 7.5) as buffer, and 20 mM Na2SO4 (for maintaining constant the 
ionic strength), following the initial rates of the CA-catalyzed CO2 hydration reaction for a period of 10-100 s. 
The CO2 concentrations ranged from 1.7 to 17 mM for the determination of the kinetic parameters and inhibition 
constants. For each inhibitor at least six traces of the initial 5-10% of the reaction have been used for 
determining the initial velocity. The uncatalyzed rates were determined in the same manner and subtracted from 
the total observed rates. Stock solutions of inhibitor (0.1 mM) were prepared in distilled-deionized water and 
  
dilutions up to 0.01 nM were done thereafter with the assay buffer. Inhibitor and enzyme solutions were 
preincubated together for 15 min at room temperature prior to assay, in order to allow for the formation of the E-
I complex. The inhibition constants were obtained by non-linear least-squares methods using PRISM 3 and the 
Cheng-Prusoff equation, as reported earlier,21-23and represent the mean from at least three different 
determinations. All CA isofoms were recombinant ones obtained in-house as reported earlier.21-23 
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R = Ph, benzyl, substituted aryl; etc 
KI (hCA I) = 9.4 – 896.8 nM; KI (hCA II) = 1.0 – 1427 nM; KI (hCA IX) = 0.91 – 120.7 nM; KI (hCA XII) = 1.0 
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